One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis

The British Journal of Psychiatry : the Journal of Mental Science
Hiroyoshi TakeuchiGary Remington

Abstract

BackgroundAs definitions of relapse differ substantially between studies, in investigations involving data aggregation, total scores on clinical rating scales provide a more generalisable outcome.AimsTo compare total symptom trajectories for antipsychotic versus placebo treatment over a 1-year period of maintenance treatment in schizophrenia.MethodRandomised controlled trials with antipsychotic and placebo treatment arms in patients with stable schizophrenia that reported Positive and Negative Syndrome Scale and Brief Psychiatric Rating Scale total scores at more than one time point were included. Meta-regression analyses were employed using a mixed model.ResultsA total of 11 studies involving 2826 patients were included. Meta-regression analyses revealed significant interactions between group and time (PS<0.0001); both standardised total scores and per cent score changes remained almost unchanged in patients continuing antipsychotic treatment, whereas symptoms continuously worsened over time in those switching to placebo treatment.ConclusionsWhen considering long-term antipsychotic treatment of schizophrenia, clinicians must balance symptomatic and functional outcomes.

References

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1997·Archives of General Psychiatry·A C VigueraM Tohen
Nov 19, 2003·Journal of Clinical Psychopharmacology·Charles M BeasleyUNKNOWN Olanzapine Relapse Prevention Study Group
Nov 25, 2003·The Journal of Clinical Psychiatry·Teresa A PigottUNKNOWN Aripiprazole Study Group
Dec 10, 2003·Archives of General Psychiatry·Ofer AgidRobert B Zipursky
Jun 29, 2005·Schizophrenia Research·Stefan LeuchtRolf R Engel
Dec 1, 2005·The International Journal of Neuropsychopharmacology·Megan SherwoodWilliam G Honer
Feb 9, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stefan LeuchtStefan Wagenpfeil
Jul 23, 2009·BMJ : British Medical Journal·David MoherUNKNOWN PRISMA Group
Nov 6, 2009·Schizophrenia Bulletin·Michael ObermeierMichael Riedel
Apr 2, 2010·Schizophrenia Bulletin·Stefan LeuchtJohn M Davis
Dec 22, 2011·The British Journal of Psychiatry : the Journal of Mental Science·Takefumi SuzukiDavid C Mamo
Nov 23, 2012·Schizophrenia Bulletin·Erika JääskeläinenJouko Miettunen
Mar 21, 2013·Schizophrenia Bulletin·Martin Harrow, Thomas H Jobe
Aug 27, 2013·Schizophrenia Research·Robert B ZipurskyDavid L Streiner
Mar 1, 2014·Progress in Neuro-psychopharmacology & Biological Psychiatry·Qing RuiSrihari Gopal
Nov 3, 2016·The British Journal of Psychiatry : the Journal of Mental Science·Robin M MurrayDavid Taylor
Mar 10, 2017·Schizophrenia Research·Regitze Sølling WilsMerete Nordentoft

❮ Previous
Next ❯

Citations

Sep 3, 2017·The British Journal of Psychiatry : the Journal of Mental Science·Stefan Leucht, John M Davis
Sep 6, 2019·Human Psychopharmacology·Konstantinos N FountoulakisIoannis Nimatoudis
Nov 27, 2019·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hideaki TaniHiroyoshi Takeuchi
Jan 10, 2019·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·Martin LambertAnne Karow
Jan 9, 2021·Behavioural Brain Research·Jose M RubioJohn M Kane
Mar 23, 2021·Schizophrenia Bulletin·Hiroyoshi TakeuchiGary Remington

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here